Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 9, 2004. The report primarily details corporate actions regarding share buybacks and updates on directors' interests in company shares through various employee benefit trusts and plans.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to a share repurchase transaction:
- Shares Purchased: 890,000 Ordinary 25 pence shares.
- Purchase Date: March 5, 2004.
- Price per Share: 1,125.67 pence.
- Purpose: Cancellation of shares.
Material Changes
The filing reports specific changes in share ownership structures and director interests rather than operational or financial performance changes:
- Share Capital Reduction: The company reduced its share count by 890,000 shares via cancellation following a buyback authorized at the May 19, 2003 Annual General Meeting.
- US Retirement Savings Plan: The number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 18,706,770 to 18,699,478 due to fund movements on March 4, 2004, at an average price of $42.05.
- Employee Trust Transfers:
- 2,718 Ordinary Shares were transferred from the GSK Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- 1,563 Ordinary Shares were transferred from the SmithKline Beecham Employee Benefit Trust to participants in the GlaxoSmithKline Annual Investment Plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items beyond the routine disclosure of share transactions and director interests.
Key Facts for Investor Verification
- Verify the total cost of the 890,000 share buyback (890,000 shares x 1,125.67 pence) and its impact on the company's cash position.
- Confirm the current total number of outstanding shares following the cancellation of the 890,000 shares.
- Review the full details of the directors' potential interests in the US Retirement Savings Plan, GSK Trust, and SmithKline Beecham Employee Benefit Trust to assess any potential conflicts of interest.
- Note that this filing does not contain quarterly or annual financial performance data; investors should refer to the most recent Form 20-F or interim reports for revenue and profit figures.